Healthcare Costs Associated with Osteoarthritis in US Patients

Pain Practice

Volumn 12, Issue 8, 2012, Pages 633-640

  Le, T Kim ^a   Montejano, Leslie B ^b   Cao, Zhun ^b   Zhao, Yang ^a   Ang, Dennis ^c  

^a ELI LILLY AND COMPANY   (United States)

^b THOMSON REUTERS   (United Kingdom)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Economic burden; Healthcare costs; Medication treatment patterns; Osteoarthritis

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CYCLOOXYGENASE 2 INHIBITOR; HYPNOTIC SEDATIVE AGENT; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PRESCRIPTION DRUG; PROTON PUMP INHIBITOR; TRAMADOL;

AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; OSTEOARTHRITIS; OUTPATIENT; PAIN; PHARMACY; RETROSPECTIVE STUDY; UNITED STATES;

EID: 84868578818     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2012.00535.x     Document Type: Article

References (14)

1. US Centers for Disease Control and Prevention. Osteoarthritis. 2011. Available at: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm. (accessed February 1, 2011).
2. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15-25.
3. White AG, Birnbaum HG, Janagap C, Buteau S, Schein J. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med. 2008;50:998-1005.
4. Altman RD. Early management of osteoarthritis. Am J Manag Care. 2010;16(suppl Management):S41-S47.
5. Manek NJ, Lane NE. Osteoarthritis: current concepts in diagnosis and management. Am Fam Physician. 2000;61:1795-1804.
6. Corti MC, Rigon C. Epidemiology of osteoarthritis: prevalence, risk factors and functional impact. Aging Clin Exp Res. 2003;15:359-363.
7. Daul P, Grisanti J. Monitoring response to therapy in rheumatoid arthritis-perspectives from the clinic. Bull NYU Hosp Jt Dis. 2009;67:236-242.
8. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthrits of the hip and knee. Arthritis Rheum. 2000;43:1905-1915.
9. Zeni JA Jr, Axe MJ, Snyder-Mackler L. Clinical predictors of elective total joint replacement in persons with end-stage knee osteoarthritis. BMC Musculoskelet Disord. 2010;11:86.
10. Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum. 2009;60:3546-3553.
11. Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009;15:S230-S235.
12. Dunn JD, Pill MW. A claims-based view of health care charges and utilization for commercially insured patients with osteoarthritis. Manag Care. 2009;18:44-50.
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
14. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137-162.